
## **Supplementary data**

## Patterns and management of chronic obstructive pulmonary disease in urban and rural China: a community-based survey of 25,000 adults across 10 regions

Om P Kurmi PhD, Kourtney Davis PhD, Kin Bong Hubert Lam PhD, Yu Guo MSc, Julien Vaucher MD, Derrick Bennett PhD, Jenny Wang MSc, Zheng Bian MD, Huaidong Du PhD, Liming Li PhD, Robert Clarke FRCP, Zhengming Chen DPhil for the China Kadoorie Biobank Collaborative Group (members listed at the end of paper)



**Fig. S1** Venn diagram showing the repartition of participants in the study population. A= Symptom-based COPD only; B= Doctor-diagnosed COPD only; AB= Symptom-based COPD and Doctor-diagnosed COPD; C=Absence of COPD

**Table S1** Prevalence of co-morbidities (self-reported but doctor diagnosed) amongst COPD cases

		0	D4 di d	Symptom-based or
	Study	Symptom-based I COPD <sup>a</sup>	COPD <sup>b</sup>	doctor-diagnosed COPD <sup>c</sup>
Characteristics	population	% (95% CI)	% (95% CI)	% (95% CI)
All participants (%)	25011	612 (2.4)	1193 (4.8)	1586 (6.3)
Co-morbidities				
Asthma	265	15.7 (14.1, 17.2)	40.9 (38.8, 42.9)	45.7 (43.6, 47.8)
Stroke	853	3.1 (2.6, 3.6)	5.5 (4.8, 6.2)	7.6 (6.8, 8.4)
IHD	1476	4.0 (3.6, 4.5)	8.7 (8.1, 9.3)	10.4 (9.7, 11.1)
Hypertension	6330	2.7 (2.6, 2.9)	5.4 (5.1, 5.6)	7.2 (6.9, 7.4)
Lung cancer	21	2.9 (0.5, 5.3)	6.3 (2.6, 9.9)	9.2 (4.9, 13.5)
Rheumatoid arthritis	1167	4.5 (4.0, 4.9)	8.7 (8.1, 9.3)	11.2 (10.5, 11.9)
Tuberculosis	317	5.3 (4.3, 6.3)	12.7 (11.3, 14.2)	14.0 (12.6, 15.5)
Diabetes	1847	2.4 (2.1, 2.8)	4.2 (3.8, 4.6)	5.9 (5.5, 6.3)

<sup>&</sup>lt;sup>a</sup>Symptom-based COPD are those with self-reported chronic cough i.e. productive cough for at least 3 months for 2 consecutive years; <sup>b</sup>COPD defined by history of doctor diagnosis of COPD where COPD= COPD and/or Chronic bronchitis and/or emphysema; <sup>c</sup>Either <sup>a</sup> or <sup>b</sup>; Standardised for region, age group and gender as appropriate

Characteristics	Total <sup>a</sup>	Rural <sup>b</sup>	Urban <sup>b</sup>
Participants	1586	911	675
CAT-score			
<10	882 (56.0)	499 (54.8)	383 (56.9)
10-20	514 (33.0)	305 (33.5)	209 (30.9)
>20	190 (11.0)	107 (11.8)	83 (12.2)
Understanding of condition and treatmen	nt		
Well informed	295 (17.8)	115 (12.6)	180 (26.7)
Inadequately/poorly informed	1114 (71.3)	686 (75.4)	428 (63.4)
Don't know	177 (10.9)	110 (12.0)	67 (9.9)
Self-reported severity of chronic lung dis	sease		
Severe/Very severe	295 (18.7)	192 (21.1)	103 (15.2)
Moderate	578 (36.5)	319 (35.1)	259 (38.4)
Mild/very mild	713 (44.8)	400 (43.9)	313 (46.4)
Health care professional consultations(la	•		
No	721 (46.8)	459 (50.3)	262 (38.8)
Yes	865 (53.2)	452 (49.7)	413 (61.2)
General physician	536 (32.7)	294 (32.3)	242 (35.8)
Respiratory specialist	305 (19.1)	141 (15.5)	164 (24.4)
Cardiologist/heart specialist	74 (4.5)	37 (4.1)	37 (5.5)
Traditional Chinese medicine doctor	132 (7.7)	73 (8.0)	59 (8.7)
Other medical professional	104 (6.2)	59 (6.5)	45 (6.6)
Hospitalisation for COPD (last 12 month	=		
None	1333 (84.6)	765 (84.7)	568 (84.7)
One	182 (12.0)	107 (11.9)	75 (11.2)
≥Two	58 (3.4)	31 (3.4)	27 (4.1)
Oxygen therapy at home (last 12 months	-		
No	1523 (96.7)	881 (98.0)	642 (96.1)
Yes	44 (3.3)	18 (2.0)	26 (3.9)
Vaccination (last 12 months)	1507 (00 5)	075 (00.4)	050 (00.0)
No	1527 (96.5)	875 (96.1)	652 (96.6)
Yes	59 (3.5)	36 (3.9)	23 (3.4)
Influenza vaccination	54 (2.9)	33 (3.6)	21 (3.1)
Pneumococcal vaccination	14 (1.0)	6 (0.7)	8 (1.2)
Medication for COPD exacerbation (last	•	000 (00 4)	440 (05.0)
No	1072 (68.2)	632 (69.4)	440 (65.2)
Yes	514 (31.8)	279 (30.6)	235 (34.8)
Antibiotics	483 (30.2)	264 (29.0)	219 (32.4)
Oral steroids	107 (6.5)	58 (6.4)	49 (7.2)
Injectable steroids  Number of COPD exacerbations after n	70 (4.6)	30 (3.3)	40 (5.9)
None		722 (70.4)	462 (69 E)
One	1185 (74.6)	723 (79.4)	462 (68.5)
one ≥ Two	202 (12.9) 199 (12.6)	80 (8.8) 108 (11.8)	122 (18.0)
	199 (12.0)	100 (11.0)	91 (13.4)
Prescribed medication (last 7 days) No	1447 (90.4)	940 (02.2)	607 (90.0)
Yes	1447 (89.4) 139 (10.6)	840 (92.2) 71 (7.8)	607 (89.9) 68 (10.1)
Short-acting bronchodilators	25 (2.0)	12 (1.3)	13 (1.9)
_	25 (2.0) 16 (1.2)		
Long-acting bronchodilators  Oral bronchodilators	19 (1.2)	6 (0.7) 8 (0.9)	10 (1.5) 11 (1.6)
	19(1.1)	0 (0.9)	11(1.0)
Traditional Chinese medicine	33 (2.5)	18 (2.0)	15 (2.2)

<sup>a</sup>Standardised for region, age group and gender; <sup>b</sup> Standardised for age group and gender. Short acting bronchodilators (short-acting beta2-agonist/short-acting muscarinic antagonist); Long-acting bronchodilators (long-acting beta2-agonist / long-acting muscarinic antagonist)

**Table S3** Disease severity and management by different COPD criteria by smoking status

Characteristics	Total	Never-regular	Ever-regular
Participants	1586	984	602
CAT-score			
<10	882 (56.0)	539 (55.7)	343 (56.3)
10-20	514 (33.0)	320 (32.3)	194 (33.7)
>20	190 (11.0)	125 (11.9)	65 (10.0)
Understanding of condition and treatment	, ,	, ,	, ,
Well informed	295 (17.8)	181 (18.8)	114 (16.8)
Inadequately/poorly informed	1114 (71.3)	696 (70.0)	418 (72.6)
Don't know	177 (10.9)	107 (11.2)	70 (10.5)
Self-reported severity of chronic lung disea	ise		
Severe/Very severe	295 (18.7)	188 (19.5)	107 (17.9)
Moderate	578 (36.5)	352 (35.3)	226 (37.8)
Mild/very mild	713 (44.8)	444 (45.3)	269 (44.4)
Health care professional consultations(last		, ,	, ,
No .	721 (46.8)	416 (42.6)	305 (51.3)
Yes	865 (53.2)	568 (57.4)	297 (48.7)
General physician	536 (32.7)	347 (34.9)	
Respiratory specialist	305 (19.1)	193 (19.9)	112 (18.3)
Cardiologist/heart specialist	74 (4.5)	45 (4.3)	29 (4.6)
Traditional Chinese medicine doctor	132 (7.7)	96 (9.2)	36 (6.1)
Other medical professional	104 (6.2)	73 (7.0)	31 (5.3)
Hospitalisation for COPD (last 12 months)	( )	( ,	- ()
None	1333 (84.6)	832 (85.1)	501 (84.0)
One	182 (12.0)	105 (11.1)	
≥ Two	58 (3.4)	37 (3.7)	21 (3.1)
Oxygen therapy at home (last 12 months)	00 (01.)	G. (G)	(0)
No	1523 (96.7)	948 (97.3)	575 (96.1)
Yes	44 (3.3)	24 (2.7)	20 (3.9)
Vaccination (last 12 months)	11 (0.0)	( )	20 (0.0)
No	1527 (96.5)	946 (96.5)	581 (96.6)
Yes	59 (3.5)	38 (3.5)	21 (3.4)
Influenza vaccination	54 (2.9)	35 (3.2)	19 (2.6)
Pneumococcal vaccination	14 (1.0)	10 (0.9)	4 (1.1)
Medication for COPD exacerbation (last 12		10 (0.5)	7 (1.1)
No	1072 (68.2)	656 (68.0)	416 (68.3)
Yes	514 (31.8)	328 (32.0)	186 (31.7)
Antibiotics	483 (30.2)	308 (30.1)	175 (30.2)
Oral steroids	107 (6.5)	64 (5.8)	43 (7.3)
Injectable steroids	70 (4.6)	44 (3.8)	26 (5.4)
Number of COPD exacerbations after med		44 (0.0)	20 (0.4)
None	1185 (74.6)	724 (75.1)	461 (74.0)
One	202 (12.9)	134 (12.7)	68 (13.1)
≥ Two	199 (12.6)	126 (12.2)	73 (12.9)
Prescribed medication (last 7 days)	199 (12.0)	120 (12.2)	73 (12.9)
No	1447 (89.4)	903 (91.0)	544 (87.7)
Yes	139 (10.6)	81 (9.0)	58 (12.3)
Short-acting bronchodilators	25 (2.0)	12 (1.3)	13 (2.7)
Long-acting bronchodilators	16 (1.2)	9 (0.9)	
Oral bronchodilators	19 (1.2)	11 (1.1)	7 (1.5) 8 (1.1)
Traditional Chinese medicine	33 (2.5)	22 (2.5)	11 (2.5)
Other treatments	94 (7.2)	55 (6.2)	
All the figures are standardised for region	±+ (1.∠)	od gondor Sho	39 (8.2)

All the figures are standardised for region, age group and gender. Short acting bronchodilators (short-acting beta2-agonist/short-acting muscarinic antagonist); Long-acting bronchodilators (long-acting beta2-agonist / long-acting muscarinic antagonist)

Table S4 Disease severity and management measures, by COPD sub-types (COPD LLN)

Study COPD % COPD % (95% doctor-diagno	
· · · · · · · · · · · · · · · · · · ·	
Participants 600 209 490	% (95% CI) 600
Lung function (mean ± SD)	000
FEV1 (L) 1.4 ± 0.1 1.5 ± 0.1 1.3 ± 0.1	1.4 ± 0.1
FVC (L) 2.4 ± 0.2 2.6 ± 0.2 2.3 ± 0.2	$2.4 \pm 0.2$
FEV1/FVC (%) 56.4 ± 2.0 58.0 ± 2.0 55.2 ± 2.0	56.4 ± 2.0
CAT-score	
<10 311 45.4 (43.1, 47.8) 50.5 (49.0, 52.1) 51.8	(50.5, 53.2)
10-20 204 34.1 (31.9, 36.3) 34.7 (33.2, 36.2) 34.0	(32.7, 35.3)
>20 85 20.4 (18.5, 22.4) 14.8 (13.7, 15.8) 14.2	(13.2, 15.1)
Awareness of condition and treatment	
	(15.2, 17.2)
	(71.8, 74.2)
· · · · · · · · · · · · · · · · · · ·	(10.0, 11.7)
Self-reported severity of chronic lung disease	(00 0 00 0)
	(23.8, 26.2)
	(36.8, 39.5)
	(35.5, 38.2)
Vaccination (last 12 months)         580         96.9 (96.1, 97.7)         96.1 (95.5, 96.7)         96.7	(96.2, 97.2)
	3 (2.8, 3.8)
	0 (2.5, 3.5)
	5 (0.3, 0.7)
Health care professional consultations(last 12 months)	5 (0.5, 0.7)
· · · · · · · · · · · · · · · · · · ·	(41.8, 44.5)
	(55.5, 58.2)
	(34.7, 37.3)
	(19.9, 22.1)
	5 (4.9, 6.1)
	2 (7.4, 8.9)
Other medical professional 31 3.5 (2.6, 4.3) 5.7 (5.0, 6.5) 5.	2 (4.6, 5.8)
Hospitalisation for COPD (last 12 months)	
	(80.2, 82.3)
	(13.2, 15.1)
	6 (4.0, 5.1)
Oxygen therapy at home (last 12 months)	
	4 (3.8, 5.0)
· · · · · · · · · · · · · · · · · · ·	(95.0, 96.2)
Medication for COPD exacerbation (last 12 months)	(62.7.66.2)
	(63.7, 66.3) (33.7, 36.3)
	(33.7, 30.3)
	(8.5, 10.1)
	2 (3.6, 4.7)
Number of COPD exacerbations after medication	2 (0.0, 4.7)
	(72.1, 74.5)
	(10.5, 12.2)
	(14.3, 16.3)
Prescribed medication (last 7 days)	, ,
No 529 90.0 (88.6, 91.5) 86.2 (85.2, 87.3) 88.2	(87.3, 89.1)
Yes 71 10.0 (8.5, 11.4) 13.8 (12.7, 14.8) 11.8	(10.9, 12.7)
	2 (1.8, 2.6)
	5 (1.2, 1.8)
	7 (1.3, 2.0)
	3 (1.0, 1.6)
	8 (2.4, 3.3)
Other treatments 44 6.3 (5.2, 7.5) 8.4 (7.5, 9.2) 7.  All data standardised for region, age group and gender as appropriate. Short acting bronchodilators (short-acting beta2-agonist/	3 (6.6, 8.1)

All data standardised for region, age group and gender as appropriate. Short acting bronchodilators (short-acting beta2-agonist/short-acting muscarinic antagonist); Long-acting bronchodilators (long-acting beta2-agonist / long-acting muscarinic antagonist)

Table S5 Use of medication among COPD cases who reported taking medication in the last 7 days or in the last 12 months prior to re-survey by gender, region, socioeconomic and smoking status (COPD LLN)

		Use of medication	Use of medication	
	Study	(%, 95% CI) Last 7	(%, 95% CI) Last 12	
Characteristics	population	days <sup>a</sup>	months <sup>b</sup>	
Participants	600	71	210	
Sex				
Men	325	12.6 (10.9, 14.4)	34.5 (32.1, 37.0)	
Women	275	10.8 (9.0, 12.6)	35.6 (32.8, 38.3)	
Area		, , ,	,	
Rural	414	9.9 (8.5, 11.4)	30.6 (28.4, 32.8)	
Urban	186	16.2 (13.6, 18.9)	44.6 (41.0, 48.1)	
Regions <sup>c</sup>				
Sichuan (R)	138	9.5 (6.9, 12.1)	9.4 (6.9, 12.0)	
Gansu (R)	73	12.5 (8.6, 16.3)	68.5 (63.2, 73.8)	
Zhejiang (R)	77	7.3 (4.4, 10.1)	25.1 (20.2, 29.9)	
Harbin (U)	47	17.7 (12.3, 23.1)	48.8 (41.4, 56.3)	
Henan (R)	49	0.0 (0.0, 0.0)	15.9 (10.4, 21.4)	
Qingdao (U)	35	13.6 (8.1, 19.2)	42.2 (34.7, 49.7)	
Hunan (R)	77	16.4 (12.1, 20.6)	47.3 (41.8, 52.8)	
Liuzhou (U)	39	26.7 (19.8, 33.5)	36.5 (28.8, 44.2)	
Haikou (U)	17	20.5 (11.8, 29.2)	57.7 (44.9, 70.4)	
Suzhou (U)	48	6.5 (3.0, 9.9)	46.3 (39.3, 53.2)	
Household income (Yuan)				
<10000	86	9.3 (7.3, 11.4)	35.4 (32.0, 38.8)	
10000 - 19999	82	17.4 (14.8, 19.9)	44.2 (40.8, 47.5)	
≥ 20000	432	11.4 (10.4, 12.5)	34.0 (32.5, 35.4)	
Education				
None	140	8.5 (6.8, 10.1)	32.6 (29.6, 35.5)	
Primary	246	13.2 (11.6, 14.8)	38.5 (36.5, 40.5)	
Secondary or tertiary	214	11.8 (10.3, 13.4)	29.9 (27.7, 32.1)	
Smoking status				
Never	304	13.1 (11.5, 14.6)	35.6 (33.5, 37.7)	
Ex-regular	92	14.6 (11.9, 17.2)	39.0 (35.8, 42.3)	
Current regular	204	10.9 (9.0, 12.8)	29.9 (27.3, 32.5)	

<sup>&</sup>lt;sup>a</sup>Medication questionnaire was completed only by those who had symptom-based COPD or history of doctor diagnosed COPD in the 2<sup>nd</sup> resurveys; Medication in last 7 days (Short-acting bronchodilators, long-acting bronchodilators, oral bronchodilators, any inhaled medications, traditional Chinese medicine and any other treatments prescribed for COPD);

b Medication in last 12 months (Antibiotics, oral corticosteroids, injectable corticosteroids). Standardised for region, age group and gender

as appropriate;

Che regions are ordered by COPD prevalence as in Figure 3.

## **Appendix 1: COPD questionnaire (Q7.5)**

The following questions are related to your chronic lung disease. Please give the answers you feel most appropriate.

1.	Ov	erall, how would you rate the severity of your	chronic	lung di	sease n	ow?		
		☐ Very severe						
		☐ Severe						
		☐ Moderate						
		☐ Mild						
		☐ Very mild						
2.	Ho	w does your doctor classify the severity of you	ur cond	ition?				
		☐ Stage1 (mild)						
		☐ Stage 2 (moderate)						
		☐ Stage 3 (severe)						
		☐ Stage 4 (very severe)						
		□ Doctor has not diagnosed or told me						
		☐ Don't know						
	hov	nptoms on wellbeing and your daily life. Pleas w strongly you feel about the two pair of the st estion.			ed to ead	ch		
				_		Score		
			0	1	2	3	4	
	1)	Frequency of your cough? 0= Never cough; 5= Cough all the time		Ш			Ц	
	2)	Amount of mucus in your chest? 0= No mucus at all; 5= Full of mucus						
	3)	Tightness of your chest? 0= Not tight at all; 5= Very tight						
	4)	Breathless when walking up a hill/one flight of 0= Not breathless; 5= Very breathless	of stairs	?				
	5)	Limitation of daily activities at home by the c 0= Not limited; 5= Very limited	onditio	n?				
	6)	Degree of confidence about leaving your hon 0= Confident; 5= Not confident at all	ne?					
	7)	Quality of sleep at night and whether it is affe	ected by	v the co	ndition?			

8) Usual levels of energy? 0= I have lots of energy; 5= I have no energy at all 4. Have you ever had your lung function tested by blowing hard into a tube (excluding the present and previous CKB tests)? □ Yes П No ☐ Don't know 5. Have you ever had your lung function tested in a cabin, called a phlethysmograph? ☐ Yes П No 6. Don't knowin the past 12 months what types of health care professionals have you seen about your condition? Yes No  $\Box$ General physician П П Respiratory specialist П Cardiologist/heart specialist П Traditional Chinese medicine doctor Local health centre or village doctor П П Other medical professional 7. In the past 12 months, how many times have you been hospitalised overnight, or longer, as a direct result of your condition? times (If none, put 0) 8. In the past 12 months, have you taken any of the following to treat worsening of your breathing problems? Yes No **Antibiotics** If ticked "NO" for all items, Go to Q9. П  $\Box$ Oral steroids Injectable steroids In the past 12 months, how many episodes of COPD exacerbation have you had when you took antibiotics, oral steroids, or injectable steroids to treat worsening of your breathing problems? (if none, put 0) \_\_\_\_ times

9. In the past seven days, have you taken any prescriptive medicine (such as

0= I sleep soundly; 5= I don't sleep soundly because of my lung condition

	inhaler	s, table	ets or something else) for the condition?
		Yes → No Don't k	If ticked, Go to Q9.1
	_		es of medication have you taken in the past seven days?
	Yes	No	
			Short-acting beta-agonists (e.g. albuterol, salbutamol)
			Short-acting anti-muscarinic agents (e.g. Atrovent, Combivent
			Long-acting beta-agonists (salmeterol/Serevent, formoterol/Foradil)
			Long-acting anti-muscarinic agent (tiotropium/Spiriva)
			Oral bronchodilators
			Long-acting beta agonist+inhaled corticosteroid combination inhalers
			Inhaled corticosteroids
			Traditional Chinese medicine
			Other treatments
10.		-	2 months have you used home oxygen for your condition?  If ticked, Go to Q10.1
	10.1 At	out ho	ow often do you use oxygen at home?
			ays
11.	In the shot)'	•	2 months, have you had an influenza vaccine (also called a flu
		Yes No Don't k	now
12.		-	2 months, have you had a vaccine or shot which protects you umonia?

	☐ Yes
	□ No
	☐ Don't know
13.	How well informed do you feel you are about your condition and its treatment?
	☐ Well informed
	☐ Less than adequately informed
	☐ Very poorly informed
	☐ Don't know